Molecular Partners AG (XSWX:MOLN) ROE % Adjusted to Book Value : -36.47% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG ROE % Adjusted to Book Value?

Molecular Partners AG's ROE % for the quarter that ended in Mar. 2024 was -26.26%. Molecular Partners AG's PB Ratio for the quarter that ended in Mar. 2024 was 0.72. Molecular Partners AG's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -36.47%.

Molecular Partners AG ROE % Adjusted to Book Value Historical Data

The historical data trend for Molecular Partners AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG ROE % Adjusted to Book Value Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-7.12

-13.79

-11.10

73.22

-47.06

Molecular Partners AG Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-32.31	-34.73	-35.00	-66.34	-36.47

Competitive Comparison of Molecular Partners AG's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Molecular Partners AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's ROE % Adjusted to Book Value falls into.

Molecular Partners AG ROE % Adjusted to Book Value Calculation

Molecular Partners AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-30.12%	/	0.64
	=	-47.06%

Molecular Partners AG's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-26.26%	/	0.72
	=	-36.47%

Molecular Partners AG ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.